Tag: Diabetes: Type II
Comprehensive Approach Advised for Managing CV Risk in T2DM
In addition to managing all cardiovascular risk factors, providers must consider social determinants of health
Inequities Seen in GLP-1 RA Use for Type 2 Diabetes in the U.S.
Asian, Black, Hispanic, and low-income patients less likely to receive treatment with a glucagon-like peptide-1 receptor agonist for T2DM
Excess Cortisol From Benign Adrenal Tumors Ups Hypertension Risk
Blood pressure, glucose levels should be checked regularly in individuals with mild autonomous cortisol secretion from benign adrenal tumors
Holidays Complicate Diabetes Management, Patients Report
Half of U.S. adults with diabetes say managing diabetes is more difficult during the holidays versus other times of the year
Transgender Women Have Increase in T2DM Versus Cisgender Females
No differences in prevalence, incidence of T2DM across other comparison groups, including those receiving gender-affirming hormone therapy
Risk for Diabetic Retinopathy Up for Children With Type 2 Diabetes
Risk significantly increased for requiring pars plana vitrectomy by 15 years after diagnosis for children with type 2 versus type 1 diabetes
Bariatric Surgery Cuts Hepatic Steatosis in Obesity and T2DM
Similar decline in liver fat fraction seen for sleeve gastrectomy, Roux-en-Y gastric bypass from surgery to one-year follow-up
Dasatinib Beneficial in Type 2 Diabetes
Patients treated with dasatinib had mean reduction in serum glucose concentration and relative decrease in body weight
Alendronate May Reduce Risk for Type 2 Diabetes
Adjusted odds ratio for type 2 diabetes further reduced for those with more than eight years of alendronate use
SGLT2 Inhibitors May Cut Risk for Heart Failure Hospitalization
SGLT2 inhibitors, compared with GLP-1 RAs, linked to lower risk for heart failure hospitalization in patients with T2DM, with or without CVD
